Previously, the researchers attempted to enhance TRAIL antitumor activity by functionalizing it with tumor-homing peptides bearing integrin recognition motif RGD (arginine–glycine–aspartic acid), particularly binding to integrins αvβ3/5, which are vastly expressed in most tumor cells and the tumor vasculature. The gene discussed is TNFSF10; the disease is neoplasm.